Eli Lilly said Ventyx’s pipeline has potential applications in cardiometabolic health, neurodegeneration, and autoimmunity.

Multiple clinical data readouts expected in 2026 present opportunity for substantial value creationKOASTAL-2 and -3 on track for consolidated ...

OPKO Health has improved its financial position by selling most of BioReference, reducing cash burn, and strengthening its balance sheet. Ngenla's profit share with Pfizer has underperformed ...

Absci Corporation has announced significant advancements in its drug development pipeline during its 2024 R&D Day. The company highlighted the selection of ABS-201, a novel anti-PRLR antibody ...

Japan-based Takeda Pharmaceutical, which has its ADR listed on the NYSE, gets a buy rating today, agreeing with the analyst consensus. Besides a diverse drug portfolio across multiple segments, they ...

ZyVersa announces pipeline advancements with IC 100 for obesity-related inflammation and VAR 200 for diabetic kidney disease. Meetings welcomed. ZyVersa Therapeutics, Inc. is progressing in developing ...

After a sluggish first half, the drug and biotech sector has staged a recovery over the past two to three months. This ...

Discover how AI is revolutionizing RNA drug development in a new article published in Engineering. Learn about the potential ...

The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...